Hyderabad: The clinical trials performed at Nizam’s Institute of Medical Sciences (NIMS) for India’s first Coronavirus vaccine COVAXIN have entered the final level.
As part of clinical trials for COVAXIN, on Wednesday, August 12, NIMS in Hyderabad administered the dose of the vaccine to 11 volunteers.
NIMS doctors said the condition of volunteers treated with the drug in two phases was satisfactory, and it is said that COVAXIN has yielded better results. Doctors said the COVAXIN zero dose was administered to 50 volunteers in the first step, and all of them are said to be healthy in their health condition.
Volunteers’ health status was tracked for 14 days from the date of the first dose, and those who had completed their 14 days from the date of the first dose were selected for the booster dose, physicians said.
All that have been treated with the booster dose will be under doctors’ observation for 24 hours, they will be sent home afterwards. NIMS management said in the second phase seven individuals were administered the booster dose.
Doctors said that excess phone and video calls are tracked twice a day to volunteers provided with the booster dose. Volunteers who were treated with COVAXIN are in a good health state.
The Indian Council for Medical Research(ICMR), in collaboration with Bharat Biotech International Limited (BBIL), is developing COVAXIN medicine. In addition to NIMS, the ICMR has listed 12 other healthcare facilities located in Hyderabad, Visakhapatnam, New Delhi, Rohtak, Kanpur (Uttar Pradesh), Patna, Belgaum (Karnataka), Nagpur, Kattankulathur (Tamil Nadu), Gorakhpur Goa and Arya Nagar. (INN)